drugset / Trial / NCT04830449

Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

NCT04830449

Phase 3 Completed 122 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2 alone in patients with essential hypertension inadequately controlled on RLD2001-2 monotherapy.

Timeline

Start
2020-10-29
Primary completion
2021-08-24
Completion
2021-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1904-2 Unknown Oral
Comparator RLD2001-2 Unknown Oral